| (19) |
 |
|
(11) |
EP 1 541 551 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
published in accordance with Art. 158(3) EPC |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
09.11.2005 Bulletin 2005/45 |
| (43) |
Date of publication: |
|
15.06.2005 Bulletin 2005/24 |
| (22) |
Date of filing: 18.07.2003 |
|
| (51) |
International Patent Classification (IPC)7: C07D 207/16, C07D 401/12, C07D 401/14, C07D 403/12, C07D 405/12, C07D 451/04, A61K 31/4025, A61K 31/4155, A61K 31/439, A61K 31/454, A61K 31/4545, A61K 31/5377, A61K 31/541, A61P 3/10, A61P 43/00, C07D 409/12 |
| (86) |
International application number: |
|
PCT/JP2003/009179 |
| (87) |
International publication number: |
|
WO 2004/009544 (29.01.2004 Gazette 2004/05) |
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
Designated Extension States: |
|
AL LT LV MK |
| (30) |
Priority: |
23.07.2002 JP 2002213654
10.09.2002 JP 2002264450
|
| (71) |
Applicant: Astellas Pharma Inc. |
|
Chuo-ku,
Tokyo (JP) |
|
| (72) |
Inventors: |
|
- HAYAKAWA, Masahiko
c/o Yamanouchi Pharmaceut. Co.
Tsukuba-shi, Ibaraki 305-8585 (JP)
- NEGORO, Kenji
c/o Yamanouchi Pharmaceutical Co.Ltd
Tsukuba-shi, Ibaraki 305-8585 (JP)
- MIYAMOTO, Satoshi
c/o Yamanouchi Pharmaceutical Co
Tsukuba-shi, Ibaraki 305-8585 (JP)
- SUZUKI, Takayuki
c/o Yamanouchi Pharmaceutical Co.
Tsukuba-shi, Ibaraki 305-8585 (JP)
- MARUYAMA, Tatsuya
c/o Yamanouchi Pharmaceutical Co
Tsukuba-shi, Ibaraki 305-8585 (JP)
- NAKANO, Ryosuke
c/o Yamanouchi Pharmaceutical Co.
Tsukuba-shi, Ibaraki 305-8585 (JP)
|
| (74) |
Representative: HOFFMANN EITLE |
|
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München
81925 München (DE) |
|
| |
|
| (54) |
2-CYANO-4-FLUOROPYRROLIDINE DERIVATIVE OR ITS SALT |
(57) Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity,
and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes),
especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant
disorders, and obesity.